Precipio, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $42.5M
- Price
- $30.45
- % Change (Daily % change from the live per-ticker quote feed.)
- +3.47%
- Volume
- 69.6K
About
Precipio, Inc., based in New Haven, Connecticut, functions as a healthcare solutions provider within the United States. The company delivers a range of diagnostic products, reagents, and services, specifically offering diagnostic testing for blood cancers. Its advanced offerings include IV-Cell, a unique cell culture media capable of simultaneously growing four types of hematopoietic cell lineages, and HemeScreen, a comprehensive collection of genetic diagnostic panels. Precipio also develops COVID-19 antibody tests. A notable proprietary innovation is ICE-COLD PCR, a patented technology designed to boost the sensitivity of molecular tests, with kits for this technology also sold to biopharmaceutical customers. Additionally, Precipio, Inc. collaborates with academic institutions dedicated to cancer research, diagnosis, and therapy.
Quick stats
Shares outstanding1.8M
Computed float1.6M
Float / shares92.0%
Key info
SectorHealthcare
IndustryMedical - Diagnostics & Research
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001043961
Websitehttps://www.precipiodx.com
AI Summary
AI-generated1/19
majorbullishearnings
Precipio Announces Q2-2026 Financial Results
Precipio reported record quarterly revenue of $7.0 million, up 22% year-over-year, marking the first time revenue has surpassed $7 million in the company's history.
The company achieved positive Adjusted EBITDA of $0.4 million, a turnaround from a loss in the prior quarter, driven by revenue growth and lower stock-based compensation.
Operations generated $0.7 million in cash flow, resulting in a quarter-end cash balance exceeding $3 million, up from $1.1 million a year ago, achieved without external financing.